Literature DB >> 1883953

Chemotactic potency of recombinant human neutrophil attractant/activation protein-1 (interleukin-8) for polymorphonuclear leukocytes of different species.

A Rot1.   

Abstract

In order to establish the species cross-reactivity of the human neutrophil attractant/activation protein-1 (interleukin-8, NAP-1/IL-8) and find which experimental species are responsive to the human cytokine, blood polymorphonuclear leukocytes (PNMLs) were isolated from chicken, dog, goat, guinea-pig, monkey, mouse, pig, rabbit, and rat and their in vitro migration in response to this cytokine was investigated. PMNLs from all of the tested species migrated in response to recombinant human NAP-1/IL-8 (rhNAP-1/IL-8). The potency of rhNAP-1/IL-8 for the PMNLs of different species varied and was considerably lower than its potency for human cells. The morphological study combined with the leukocyte enumeration in the intradermal rhNAP-1/IL-8 injection sites established an in vivo proinflammatory potency of rhNAP-1/IL-8 for rabbit and rat that was comparable to the observed in vitro chemotactic potency of rhNAP-1/IL-8 for neutrophils of these species.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1883953     DOI: 10.1016/1043-4666(91)90006-y

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  23 in total

1.  A major role for neutrophils in experimental bullous pemphigoid.

Authors:  Z Liu; G J Giudice; X Zhou; S J Swartz; J L Troy; J A Fairley; G O Till; L A Diaz
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  Effect of substance P and somatostatin on migration of polymorphonuclear (PMN) cells in vitro.

Authors:  G Partsch; M Matucci-Cerinic
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

3.  Characterization of the pharmacological profile of the potent LTB4 antagonist CP-105,696 on murine LTB4 receptors in vitro.

Authors:  H J Showell; R Breslow; M J Conklyn; G P Hingorani; K Koch
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatect tumors.

Authors:  A S Haqqani; J K Sandhu; H C Birnboim
Journal:  Neoplasia       Date:  2000 Nov-Dec       Impact factor: 5.715

5.  CXC chemokine redundancy ensures local neutrophil recruitment during acute inflammation.

Authors:  D G Remick; L B Green; D E Newcomb; S J Garg; G L Bolgos; D R Call
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

6.  Infiltration of neutrophils by intrapleural injection of tumour necrosis factor, interleukin-1, and interleukin-8 in rats, and its modification by actinomycin D.

Authors:  I Utsunomiya; M Ito; K Watanabe; S Tsurufuji; K Matsushima; S Oh
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

7.  Differential cytokine mRNA expression in heterophils isolated from Salmonella-resistant and -susceptible chickens.

Authors:  Christina L Swaggerty; Michael H Kogut; Pamela J Ferro; Lisa Rothwell; Igal Y Pevzner; Pete Kaiser
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

8.  Effects of interleukin-8 on nonspecific resistance to infection in neutropenic and normal mice.

Authors:  M T Vogels; I J Lindley; J H Curfs; W M Eling; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo.

Authors:  G L Kukielka; C W Smith; G J LaRosa; A M Manning; L H Mendoza; T J Daly; B J Hughes; K A Youker; H K Hawkins; L H Michael; A Rot; M L Entman
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

10.  In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma.

Authors:  C R Turner; R Breslow; M J Conklyn; C J Andresen; D K Patterson; A Lopez-Anaya; B Owens; P Lee; J W Watson; H J Showell
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.